Exhibit 99


         BestNet Communications Announces Sale of Phone Business Assets


GRAND RAPIDS,  Mich.--(PR Newswire) -- January 12, 2007 - BestNet Communications
Corp. (OTCBB: BESC - News) announced today that it has filed a Current Report on
Form 8-K with the Securities and Exchange Commission  reporting the sale of most
of the assets of its telephone business to Interactive Media Technologies, Inc.,
a privately held company located in Boca Raton,  Florida.  The sale for cash did
not include  BestNet's  rights under its license from  Softalk,  Inc. The actual
transfer of the assets is expected to occur within forty-five days. According to
Mr. Stanley L. Schloz,  BestNet's  Chief  Executive  Officer,  "The  transaction
supports our  strategy to focus on our medical  subsidiary,  Oncologix,  and has
stopped the phone business drain on cash. We are also pleased that our telephone
customers  will now have the  opportunity  of  continuing  to receive  telephone
services with Interactive Media Technologies,  a highly respected participant in
the telecommunications industry."

Mr.  Schloz went on to say that  Oncologix  has  completed  the  formation  of a
Scientific  Advisory  Board  (SAB).  The SAB,  along with its Chief  Medical and
Science  Officer  Andrew  S.  Kennedy,   MD,  will  provide  advisement  on  the
development and testing of the company's Oncosphere System.

The SAB  membership  represents  key areas of expertise  involved in microsphere
brachytherapy;  radiation oncology, interventional radiology, and medical/health
physics. The members are as follow:

     >>   Mohan  Suntharalingam,   MD,  Radiation  Oncologist  -  University  of
          Maryland

     >>   Scott Sailer, MD - Radiation Oncologist - Wake Radiology

     >>   Anne  Roberts,   MD,   Interventional   Radiologist  -  University  of
          California San Diego

     >>   Raoul  Bonan,  MD  -  Interventional  Cardiologist  -  Montreal  Heart
          Institute

     >>   Tim Fox, PhD - Medical Physicist - Emory University

     >>   Cedric Yu, DSc - Medical Physicist - University of Maryland

Mr. Drew Green, Chairman and CEO of Oncologix, commented that "We are pleased to
have a team of this caliber that brings a depth of knowledge  and  experience in
developing  and  executing  on animal  and  clinical  studies  in support of FDA
approvals for a wide range of medical fields."




Dr.  Kennedy  added,  "The  experience  of  these  individuals   represents  the
development  of  new  technologies,  designing  and  participating  in  clinical
studies,  leading their respective medical  societies,  and interacting with the
FDA as physicians  and advisors.  I believe that as a group we can challenge the
medical  community and Oncologix to develop a plan for the Oncosphere  that will
advance the field of microsphere brachytherapy through evidence-based medicine."